Novartis AG (NOT) Stock Forecast & Price Target

22 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NOT Analyst Ratings

Moderate Buy

5 Buy

7 Hold

1 Sell

Based on 13 analysts giving stock ratings to

Novartis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NOT Stock 12 Month Forecast

Average Price Target

€136.69

▼(-1.31% Downside)

Based on 13 Wall Street analysts offering 12 month price targets for Novartis AG in the last 3 months. The average price target is €136.69 with a high forecast of €149.82 and a low forecast of €117.72. The average price target represents a -1.31% change from the last price of €138.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"95":"€95","150":"€150","108.75":"€108.8","122.5":"€122.5","136.25":"€136.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":149.82128,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€149.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":136.6875963636364,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€136.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":117.71672,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€117.72</span>\n  </div></div>","useHTML":true}}],"tickPositions":[95,108.75,122.5,136.25,150],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,135.68,136.76779076923077,137.85558153846154,138.9433723076923,140.0311630769231,141.11895384615386,142.20674461538462,143.2945353846154,144.38232615384615,145.47011692307692,146.5579076923077,147.64569846153847,148.73348923076924,{"y":149.82128,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,135.68,135.75750741258742,135.83501482517482,135.91252223776226,135.99002965034967,136.06753706293708,136.1450444755245,136.22255188811192,136.30005930069933,136.37756671328674,136.45507412587415,136.53258153846159,136.610088951049,{"y":136.6875963636364,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,135.68,134.29820923076923,132.91641846153846,131.5346276923077,130.15283692307693,128.77104615384616,127.38925538461538,126.00746461538462,124.62567384615384,123.24388307692308,121.86209230769231,120.48030153846153,119.09851076923077,{"y":117.71672,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":96.049,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.635,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.994,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.972,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.704,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.882,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.918,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.94,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.44,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.76,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.42,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.68,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€149.82

Average Price Target€136.69

Lowest Price Target€117.72

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Richard Vosser

J.P. Morgan

€144.47

Buy

4.31%

Upside

Reiterated

08/10/26

J.P. Morgan Keeps Their Buy Rating on Novartis AG (NOVN)

Graham Parry

Citi

―

Buy

―

Reiterated

08/07/26

Morgan Stanley’s Graham Parry Reiterates Buy on Novartis, Citing Pelacarsen Upside and Above‑Consensus EPS Outlook

Shelby Tucker

TD Cowen

€147.68

Hold

6.63%

Upside

Reiterated

07/27/26

Novartis: Solid Fundamentals but Balanced Risk-Reward Justify Hold Rating

Kerry Holford

Berenberg Bank

€117.72→€128.42

Hold

-7.28%

Downside

Reiterated

07/27/26

Berenberg Bank Keeps Their Hold Rating on Novartis AG (NOVN)

Matthew Weston

UBS

€124.14

Hold

-10.37%

Downside

Reiterated

07/22/26

Novartis AG (NOVN) Receives a Hold from UBS

Justin Smith

Bernstein

€133.77→€142.33

Hold

2.77%

Upside

Assigned

07/22/26

Novartis AG (NOVN) Receives a Hold from Bernstein

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

07/22/26

Novartis AG (NOVN) Gets a Hold from DZ BANK AG

Emmanuel Papadakis

Deutsche Bank

€149.82

Buy

8.17%

Upside

Reiterated

07/22/26

Deutsche Bank Keeps Their Buy Rating on Novartis AG (NOVN)

James Gordon CFA

Barclays

€128.42→€133.77

Hold

-3.42%

Downside

Reiterated

07/22/26

James Quigley

Goldman Sachs

€118.79→€120.93

Sell

-12.69%

Downside

Reiterated

07/22/26

Novartis: Sell Rating Maintained as Timing-Driven Upside Keeps Risk‑Reward Unfavorable; $111 Price Target Reaffirmed

Sachin Jain

Bank of America Securities

€149.82

Buy

8.17%

Upside

Reiterated

07/21/26

Novartis: Buy Rating Reiterated on Q2 Beat, Strong Growth Brands and Pipeline Upside; Price Target Maintained at $140

Michael Leuchten

Jefferies

€117.72

Hold

-15.01%

Downside

Reiterated

07/21/26

Jefferies Keeps Their Hold Rating on Novartis AG (NOVN)

Thibault Boutherin

Morgan Stanley

€144.47

Buy

4.31%

Upside

Reiterated

06/25/26

Novartis: Buy Rating Reiterated on Pelacarsen Cardiovascular Upside; $135 Price Target Unchanged

David Evans

Kepler Capital

€144.47

Buy

4.31%

Upside

Reiterated

05/08/26

Kepler Capital Remains a Buy on Novartis AG (NOVN)

Rajesh Kumar

HSBC

€95.24→€101.66

Sell

-26.60%

Downside

Reiterated

03/17/26

Novartis price target raised to CHF 95 from CHF 89 at HSBCNovartis price target raised to CHF 95 from CHF 89 at HSBC

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Richard Vosser

J.P. Morgan

€144.47

Buy

4.31%

Upside

Reiterated

08/10/26

J.P. Morgan Keeps Their Buy Rating on Novartis AG (NOVN)

Graham Parry

Citi

―

Buy

―

Reiterated

08/07/26

Morgan Stanley’s Graham Parry Reiterates Buy on Novartis, Citing Pelacarsen Upside and Above‑Consensus EPS Outlook

Shelby Tucker

TD Cowen

€147.68

Hold

6.63%

Upside

Reiterated

07/27/26

Novartis: Solid Fundamentals but Balanced Risk-Reward Justify Hold Rating

Kerry Holford

Berenberg Bank

€117.72→€128.42

Hold

-7.28%

Downside

Reiterated

07/27/26

Berenberg Bank Keeps Their Hold Rating on Novartis AG (NOVN)

Matthew Weston

UBS

€124.14

Hold

-10.37%

Downside

Reiterated

07/22/26

Novartis AG (NOVN) Receives a Hold from UBS

Justin Smith

Bernstein

€133.77→€142.33

Hold

2.77%

Upside

Assigned

07/22/26

Novartis AG (NOVN) Receives a Hold from Bernstein

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

07/22/26

Novartis AG (NOVN) Gets a Hold from DZ BANK AG

Emmanuel Papadakis

Deutsche Bank

€149.82

Buy

8.17%

Upside

Reiterated

07/22/26

Deutsche Bank Keeps Their Buy Rating on Novartis AG (NOVN)

James Gordon CFA

Barclays

€128.42→€133.77

Hold

-3.42%

Downside

Reiterated

07/22/26

James Quigley

Goldman Sachs

€118.79→€120.93

Sell

-12.69%

Downside

Reiterated

07/22/26

Novartis: Sell Rating Maintained as Timing-Driven Upside Keeps Risk‑Reward Unfavorable; $111 Price Target Reaffirmed

Sachin Jain

Bank of America Securities

€149.82

Buy

8.17%

Upside

Reiterated

07/21/26

Novartis: Buy Rating Reiterated on Q2 Beat, Strong Growth Brands and Pipeline Upside; Price Target Maintained at $140

Michael Leuchten

Jefferies

€117.72

Hold

-15.01%

Downside

Reiterated

07/21/26

Jefferies Keeps Their Hold Rating on Novartis AG (NOVN)

Thibault Boutherin

Morgan Stanley

€144.47

Buy

4.31%

Upside

Reiterated

06/25/26

Novartis: Buy Rating Reiterated on Pelacarsen Cardiovascular Upside; $135 Price Target Unchanged

David Evans

Kepler Capital

€144.47

Buy

4.31%

Upside

Reiterated

05/08/26

Kepler Capital Remains a Buy on Novartis AG (NOVN)

Rajesh Kumar

HSBC

€95.24→€101.66

Sell

-26.60%

Downside

Reiterated

03/17/26

Novartis price target raised to CHF 95 from CHF 89 at HSBCNovartis price target raised to CHF 95 from CHF 89 at HSBC

Stocks with the Highest Top Analyst Consensus in the General Sector

STDNStandard Nuclear

SKHYSK Hynix

ITGITG Inc. Class A

LIMENeutron Holdings, Inc.

EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novartis AG

3 Months

David EvansKepler Capital

Success Rate

23/31 ratings generated profit

Average Return

+4.10%

Copying David Evans's trades and holding each position for 3 Months would result in 74.19% of your transactions generating a profit, with an average return of +4.10% per trade.

1 Year

David EvansKepler Capital

Success Rate

31/31 ratings generated profit

Average Return

+15.45%

Copying David Evans's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +15.45% per trade.

2 Years

David EvansKepler Capital

Success Rate

31/31 ratings generated profit

Average Return

+29.61%

Copying David Evans's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +29.61% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NOT Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NOT has received 16 Buy Ratings, 13 Hold Ratings, and 2 Sell Ratings. NOT average Analyst price target in the past 3 months is 136.69.

Each month's total comprises the sum of three months' worth of ratings.

NOT Financial Forecast

NOT Earnings Forecast

Next quarter’s earnings estimate for NOT is €1.93 with a range of €1.79 to €2.02. The previous quarter’s EPS was €2.09. NOT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year NOT has Performed in-line its overall industry.

NOT Sales Forecast

Next quarter’s sales forecast for NOT is €12.68B with a range of €12.44B to €12.91B. The previous quarter’s sales results were €12.26B. NOT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year NOT has Performed in-line its overall industry.

NOT Stock Forecast FAQ

What is DE:NOT’s average 12-month price target, according to analysts?

Based on analyst ratings, Novartis AG’s 12-month average price target is 136.69.

What is DE:NOT’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for DE:NOT, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novartis AG a Buy, Sell or Hold?

Novartis AG has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 7 hold ratings and 1 sell ratings.

What is Novartis AG’s share price target?

The average share price target for Novartis AG is 136.69. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €149.82 ,and the lowest forecast is €117.72. The average share price target represents -1.31% Decrease from the current price of €138.5.

What do analysts say about Novartis AG?

Novartis AG’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of Novartis AG?

To buy shares of DE:NOT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Novartis AG (NOT) Stock Forecast & Price Target

NOT Analyst Ratings

NOT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novartis AG

NOT Analyst Recommendation Trends

NOT Financial Forecast

NOT Earnings Forecast

NOT Sales Forecast

NOT Stock Forecast FAQ

Detailed List of Analyst Forecasts